Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Current Period Unaudited)

v3.23.3
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 25,598 $ 7,082
Accounts receivable 76 12
Lease receivable 0 15,527
Inventory 891 278
Assets held for sale 0 47
Prepaid expenses and other current assets 172 263
Total current assets 26,737 23,209
Non-current assets    
Property, plant and equipment, net 12,387 7,343
Intellectual property, net 326 461
Investment in LINICO 2,000 2,000
Other assets 532 489
Total non-current assets 15,245 10,293
Total assets 41,982 33,502
Current liabilities    
Accounts payable 987 1,075
Accrued expenses 2,256 1,780
Building purchase deposit 0 3,250
Lease liability, current portion 312 307
Note payable, current portion 34 5,899
Total current liabilities 3,589 12,311
Non-current liabilities    
Lease liability, non-current portion 38 275
Note payable, non-current portion 2,916 0
Total liabilities 6,543 12,586
Commitments and contingencies (see Note 13)
Stockholders’ equity    
Common stock; $0.001 par value; 200,000,000 shares authorized; 108,200,351 and 107,771,785, shares issued and outstanding as of September 30, 2023, respectively and 79,481,751 shares issued and outstanding as of December 31, 2022 108 79
Additional paid-in capital 249,036 220,114
Accumulated deficit (213,189) (199,277)
Treasury stock, at cost; common shares: 428,566 and nil as of September 30, 2023 and December 31, 2022, respectively (516) 0
Total stockholders’ equity 35,439 20,916
Total liabilities and stockholders’ equity $ 41,982 $ 33,502